BRAND PORTFOLIO

You are here:
  • Neuropsychiatry

    BRIVATOP

    Neuropsychiatry

    Brivaracetam is a third-generation antiepileptic racetam derivative and a 4-n-propyl analogue of levetiracetam. It is used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 time’s higher affinity than levetiracetam. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic…

    Know More
  • Neuropsychiatry

    Levialfa

    Levetiracetam

    Levialfa (Levetiracetam) is a drug within the pyrrolidine class that is used to treat various types of seizures originates from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). It possesses a wide therapeutic index and little-to-no potential to…

    Know More
  • Neuropsychiatry

    Nudival

    Divalproex Sodium

    NUDIVAL (Divalproex Sodium) is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Valproic acid is clear, colorless to pale yellow, slightly viscous liquid, and sparingly soluble in water, whereas sodium valproate is a white crystalline, hygroscopic, and highly soluble in water and alcohol.

    Know More
  • Neuropsychiatry

    Ultramate

    Topiramate

    Ultramate (Topiramate) is an anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass…

    Know More